Mylan Issues Voluntary Recall of Some EpiPen Auto-Injectors

Share this content:
Mylan Issues Voluntary Recall of Some EpiPen Auto-Injectors
Mylan Issues Voluntary Recall of Some EpiPen Auto-Injectors

MONDAY, April 3, 2017 (HealthDay News) -- Mylan, the maker of EpiPen, says it is recalling select lots of EpiPen and EpiPen Jr. due to a defect that might render it difficult to activate in an emergency.

Mylan said the recall was prompted by two reports -- both occurring outside the United States -- of the products' failure to activate because of a potential defect in a component part.

"The incidence of the defect is extremely rare, and testing and analysis across the potentially impacted lots has not identified any units with a defect," the company said in a news release. "However, the recall is being expanded to include additional lots as a precautionary measure out of an abundance of caution. The recall impacts the 0.3 mg and 0.15 mg strengths of EpiPen Auto-Injector. None of the recalled lots include the authorized generic for EpiPen Auto-Injector."

Consumers can get a detailed list of EpiPen and EpiPen Jr. lots under recall by going to the company's website at mylan.com. They can also call Mylan at 877-796-9526. Consumers can receive a replacement of the recalled devices for free by calling 877-650-3494.

Meridian Medical Technologies, a Pfizer company, is Mylan's manufacturing partner for EpiPen Auto-Injector.

More Information

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions



Sign up for myCME e-newsletters




More in Home

Non-Nutritive Sweeteners Don't Up Blood Glucose Levels

Non-Nutritive Sweeteners Don't Up Blood Glucose Levels

Concentration of NNSs decreases gradually over the course of observation after consumption

Laws Allowing Service Denial to Sexual Minorities Tied to Distress

Laws Allowing Service Denial to Sexual Minorities Tied ...

Laws permitting denial of services linked to increase in mental distress among sexual minorities

Antidepressant Prescribing Linked to Lasting Weight Gain

Antidepressant Prescribing Linked to Lasting Weight Gain

Risk of weight gain remained increased during at least six years of follow-up